PACIRA BIOSCIENCES INC (PCRX)
US6951271005 - Common Stock
We assign a fundamental rating of 6 out of 10 to PCRX. PCRX was compared to 194 industry peers in the Pharmaceuticals industry. PCRX has an excellent profitability rating, but there are some minor concerns on its financial health. PCRX is evaluated to be cheap and growing strongly. This does not happen too often! These ratings would make PCRX suitable for value and growth investing!
1. Profitability
1.1 Basic Checks
PCRX had positive earnings in the past year.
PCRX had a positive operating cash flow in the past year.
Of the past 5 years PCRX 4 years were profitable.
PCRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
PCRX's Return On Assets of -5.37% is fine compared to the rest of the industry. PCRX outperforms 77.08% of its industry peers.
Looking at the Return On Equity, with a value of -10.91%, PCRX is in the better half of the industry, outperforming 75.52% of the companies in the same industry.
PCRX has a better Return On Invested Capital (6.55%) than 84.90% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PCRX is significantly below the industry average of 42.22%.
The last Return On Invested Capital (6.55%) for PCRX is above the 3 year average (4.32%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.37% | ||
| ROE | -10.91% | ||
| ROIC | 6.55% |
ROA(3y)1.88%
ROA(5y)3.15%
ROE(3y)4.21%
ROE(5y)6.6%
ROIC(3y)4.32%
ROIC(5y)4.07%
1.3 Margins
In the last couple of years the Profit Margin of PCRX has declined.
PCRX has a better Operating Margin (13.59%) than 84.90% of its industry peers.
PCRX's Operating Margin has improved in the last couple of years.
With an excellent Gross Margin value of 73.82%, PCRX belongs to the best of the industry, outperforming 81.25% of the companies in the same industry.
PCRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.59% | ||
| PM (TTM) | N/A | ||
| GM | 73.82% |
OM growth 3Y-2.79%
OM growth 5Y20.05%
PM growth 3Y-43.17%
PM growth 5YN/A
GM growth 3Y-0.03%
GM growth 5Y-0.43%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PCRX is destroying value.
The number of shares outstanding for PCRX has been increased compared to 1 year ago.
The number of shares outstanding for PCRX has been increased compared to 5 years ago.
PCRX has a better debt/assets ratio than last year.
2.2 Solvency
PCRX has an Altman-Z score of 1.53. This is a bad value and indicates that PCRX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.53, PCRX is in the better half of the industry, outperforming 63.54% of the companies in the same industry.
PCRX has a debt to FCF ratio of 3.04. This is a good value and a sign of high solvency as PCRX would need 3.04 years to pay back of all of its debts.
PCRX's Debt to FCF ratio of 3.04 is amongst the best of the industry. PCRX outperforms 91.15% of its industry peers.
A Debt/Equity ratio of 0.51 indicates that PCRX is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.51, PCRX is doing worse than 64.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.51 | ||
| Debt/FCF | 3.04 | ||
| Altman-Z | 1.53 |
ROIC/WACC0.86
WACC7.58%
2.3 Liquidity
PCRX has a Current Ratio of 2.25. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
PCRX has a Current ratio of 2.25. This is comparable to the rest of the industry: PCRX outperforms 40.10% of its industry peers.
PCRX has a Quick Ratio of 1.89. This is a normal value and indicates that PCRX is financially healthy and should not expect problems in meeting its short term obligations.
PCRX has a Quick ratio (1.89) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.25 | ||
| Quick Ratio | 1.89 |
3. Growth
3.1 Past
PCRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.72%, which is quite good.
The Earnings Per Share has been growing by 22.93% on average over the past years. This is a very strong growth
Looking at the last year, PCRX shows a very strong growth in Revenue. The Revenue has grown by 29.50%.
PCRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.88% yearly.
EPS 1Y (TTM)12.72%
EPS 3Y9.9%
EPS 5Y22.93%
EPS Q2Q%9.72%
Revenue 1Y (TTM)29.5%
Revenue growth 3Y16.25%
Revenue growth 5Y14.88%
Sales Q2Q%2.83%
3.2 Future
PCRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.29% yearly.
Based on estimates for the next years, PCRX will show a quite strong growth in Revenue. The Revenue will grow by 8.72% on average per year.
EPS Next Y5.51%
EPS Next 2Y3.45%
EPS Next 3Y10.03%
EPS Next 5Y15.29%
Revenue Next Year2.32%
Revenue Next 2Y-1.59%
Revenue Next 3Y5.46%
Revenue Next 5Y8.72%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 5.45, the valuation of PCRX can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 95.31% of the companies listed in the same industry.
PCRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.96.
A Price/Forward Earnings ratio of 5.56 indicates a rather cheap valuation of PCRX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 93.75% of the companies listed in the same industry.
PCRX is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.82, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.45 | ||
| Fwd PE | 5.56 |
4.2 Price Multiples
96.35% of the companies in the same industry are more expensive than PCRX, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, PCRX is valued cheaper than 97.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.15 | ||
| EV/EBITDA | 3.69 |
4.3 Compensation for Growth
PCRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of PCRX may justify a higher PE ratio.
PEG (NY)0.99
PEG (5Y)0.24
EPS Next 2Y3.45%
EPS Next 3Y10.03%
5. Dividend
5.1 Amount
PCRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PACIRA BIOSCIENCES INC
NASDAQ:PCRX (11/21/2024, 8:00:00 PM)
After market: 17.38 0 (0%)17.38
+0.35 (+2.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap802.43M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.45 | ||
| Fwd PE | 5.56 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.99
PEG (5Y)0.24
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.37% | ||
| ROE | -10.91% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 13.59% | ||
| PM (TTM) | N/A | ||
| GM | 73.82% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.51 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.25 | ||
| Quick Ratio | 1.89 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)12.72%
EPS 3Y9.9%
EPS 5Y
EPS Q2Q%
EPS Next Y5.51%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)29.5%
Revenue growth 3Y16.25%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y